Specifically, NDRG1 can block MARCH-8-induced degradation of receptor 4, and CRC cells expressing NDRG1 are more sensitive to reagents that target death receptors such as tumor necrosis factor-related apoptosis-inducing ligands (TRAIL) [27]. Here, MARCHF8 is linked to colorectal carcinoma.